Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Caitlin Mathison

Physician Assistant, Medical Okemos, MI Physician Assistant

NPI 1194152553 CMS profile 10730851

3413 Woods Edge, Okemos, MI 48864

Open in the dashboard

General payments

$6,251

300 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Caitlin Mathison of Okemos, MI is reported in the CMS Open Payments database as having received $6,251 across 300 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,371 64
2024 General $1,458 68
2023 General $966 44
2022 General $1,282 67
2021 General $1,174 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Caitlin Mathison
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Caitlin Mathison were reported at $1,371. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Caitlin Mathison Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,174 $156 $41–$563 $132
2022 $1,282 $185 $55–$649 $149
2023 $966 $199 $58–$717 $160
2024 $1,458 $206 $62–$740 $164
2025 $1,371 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $899 49 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $522 32 payments
  3. Abbott Laboratories $458 8 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $457 22 payments
  5. AstraZeneca Pharmaceuticals LP $404 19 payments
  6. Amgen Inc. $290 15 payments
  7. E.R. Squibb & Sons, L.L.C. $276 15 payments
  8. Pfizer Inc. $259 12 payments
  9. Chiesi USA, Inc. $246 4 payments
  10. Merck Sharp & Dohme Corporation $243 13 payments
  11. Other $2,198 111 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,175 298 payments
  2. Education $76 2 payments
Products named General payments · program years 2021–2025
  1. LEQVIO $427 25 payments
  2. Kerendia $411 25 payments
  3. ENTRESTO Cardiology/Vascular Diseases $405 16 payments
  4. VERQUVO $353 19 payments
  5. ENTRESTO Cardiovascular $290 17 payments
  6. JARDIANCE $267 13 payments
  7. ELIQUIS $259 12 payments
  8. Repatha $259 13 payments
  9. KENGREAL $246 4 payments
  10. CLEVIPREX $246 4 payments
  11. Other $4,152 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

5,288

Median for Physician Assistant: 241

Drug cost

$1,219,007

Median for Physician Assistant: $4,110

Branded share of claims

34%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 342 $445,995
Entresto Sacubitril/Valsartan Brand 142 $183,756
Xarelto Rivaroxaban Brand 115 $148,794
Multaq Dronedarone Hcl Brand 64 $137,659
Farxiga Dapagliflozin Propanediol Brand 46 $57,408
Repatha Sureclick Evolocumab Brand 48 $52,103
Jardiance Empagliflozin Brand 42 $48,409
Brilinta Ticagrelor Brand 50 $45,363
Vascepa Icosapent Ethyl Brand 12 $8,616
Metoprolol Succinate Generic 435 $8,355

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$6,493

Medicare's payments for the services billed

Medicare patients

88

Average age 73

Services billed

153

39 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 56%
Arthritis 44%
Atrial fibrillation 39%
Diabetes 36%
Heart failure 35%
Chronic kidney disease 28%
COPD 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $133
$133 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $84
  • PFIZER INC. $47
$131 342 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $122
$122 142 —
VERQUVO
  • Merck Sharp & Dohme Corporation $111
$111 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $90
$90 42 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

300 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record